2024~2036년 글로벌 시장 규모, 예측 및 추세 하이라이트
The Estrogen Receptor Agonists Market size is expected to surpass USD 9 billion by 2035, observing a CAGR of nearly 7% from 2023 to 2035. The industry size of Estrogen Receptor Agonists was USD 4 billion in 2022. This growth in market demand is expected to be driven by the increasing prevalence of cardiovascular diseases. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death worldwide, accounting for approximately 17.9 million deaths annually. Hence, there is an increasing demand for various therapies to treat it, among which estrogen receptor agonists are the most preferred. It has also proven to be one of the safer treatments for cardiovascular diseases.
Postmenopausal women also commonly receive estrogen receptor agonist therapy because they experience a variety of consequences, including decreased ovarian function and decreased levels of sex steroid hormones in the blood. By 2030, the number of postmenopausal women worldwide is expected to reach 1.2 billion.
글로벌 에스트로겐 수용체 작용제 시장: 성장 동인 및 과제
Growth drivers
- The prevalence of osteoporosis is increasing . It was estimated that 18.3% of the world's population will suffer from osteoporosis in 2021. This is leading to a surge in demand for estrogen receptor agonists to treat osteoporosis. Raloxifene is the most common type of estrogen approved by the FDA for this treatment.
- Increasing number of women suffering from PCOS It is estimated that between 4% and 20% of women worldwide will suffer from PCOS in 2022. PCOS also has a great negative impact on women, causing irregular menstruation and acne. Therefore, it is necessary to receive treatment for polycystic ovary syndrome in a timely manner . Therefore, oral contraceptives (OC estrogen and progestin combined drugs) are the most widely used drug form to regulate the menstrual cycle in PCOS patients.
- Estrogen application surge in asthma There is increasing research on the use of estrogen receptor agonists in the treatment of asthma. In addition to the reproductive system, estrogen has a variety of actions in both men and women, including regulating calcium levels in inflammatory cells, cell proliferation, and differentiation. One of the hallmarks of asthma is the infiltration of inflammatory cells, such as lymphocytes, monocytes/macrophages, neutrophils, and eosinophils, into the airways, particularly eosinophilic infiltrates. Estrogen receptor agonists are therefore poised to be used. Therefore, it is expected that there will be increased investment in research activities on this topic to support the conclusions.
Challenge
- High treatment costs
- Lack of skilled personnel in this field – The use of estrogen receptor agonists is a new form of treatment that is still being researched for use in treating various diseases. Therefore, many people are not aware of this treatment. Also, due to its lack of popularity, there is a lack of professionals, especially in rural areas. Therefore, this factor is expected to hamper the growth of the estrogen receptor agonists market.
- Side effects of estrogen receptor agonists
에스트로겐 수용체 작용제 시장: 주요 통찰력
|
Base year |
2022 |
|
Forecast year |
2023-2035 |
|
CAGR |
~ 7 % |
|
Base Year Market Size (2022) |
~ US$4 billion |
|
Forecast Year Market Size (2035) |
~ USD 9 billion |
|
Area coverage |
|
Estrogen receptor for segmentation
Administrative route (oral parental)
The Estrogen Receptor Agonists Market in the Oral segment is expected to generate the highest revenue by the end of 2035. The growth of this segment is expected to increase due to its cost-effectiveness. Since parenteral drugs must be sterile and isotonic, oral drugs available in the market are cheaper, which can result in financial savings for patients. Also, oral drugs are absorbed at a faster rate. Hence, they are most preferred.
Distribution channels (hospital pharmacy retail pharmacy online pharmacy)
The hospital pharmacy segment of the estrogen receptor agonist market is expected to witness notable growth during the forecast period. Most of the estrogen receptor agonist drugs are prescribed by physicians. Therefore, hospital-affiliated pharmacies are expected to meet the growing demand for these drugs.
The in-depth analysis of the Estrogen Receptor Agonists Market includes the following segments:
|
Product Type |
|
|
Display type |
|
|
Administrative route |
|
|
Distribution Channels |
|
이 연구 보고서를 귀하의 요구 사항에 맞게 맞춤 설정하시겠습니까? 저희 연구 팀이 귀하의 요구 사항을 반영하여 효과적인 비즈니스 결정을 내리는 데 필요한 정보를 제공합니다.
이 보고서 맞춤 설정에스트로겐 수용체 작용제 산업 지역 시놉시스
APAC Market Statistics
The Asia Pacific Estrogen Receptor Agonist Market is expected to witness the highest growth by the end of 2035, driven by the increasing geriatric population in the region. In Asia Pacific, one in four people is expected to be aged 60 or above by 2050. Moreover, this transition is expected to take place relatively quickly in several countries such as the People's Republic of China, Sri Lanka, Thailand, and Vietnam. This is expected to increase the demand for estrogen receptor agonists. Geriatric people are prone to various diseases such as cardiovascular diseases, asthma, etc. Therefore, the market is expected to grow to treat or prevent the growth of diseases.
North American Market Outlook
The North American Estrogen Receptor Agonist Market is expected to witness significant growth during the forecast period. The market in the region is poised to grow due to the increasing incidence of cancer.
에스트로겐 수용체 작용제 환경을 지배하는 회사
- AstraZeneca
- Company Overview
- Business Strategy
- Main product offerings
- Financial Performance
- Key Performance Indicators (KPIs)
- Risk Analysis
- Recent Developments
- Location by region
- SWOT Analysis
- Eli Lilly & Company
- Estrogenics
- Caro Healthcare AB
- Merck KGaA
- Vibesto AB
- Oncology treatment
- Pfizer Inc.
- Tokris Bioscience
- Tokyo Chemical Industry Co. Ltd
In the News
- Positive high-level results from the FLAURA2 phase 3 trial show that AstraZeneca 's Tagrisso (osimertinib) significantly improved progression-free survival (PFS) in patients with locally advanced (stage IIIB-IIIC) or metastatic (stage IV) epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC) when combined with chemotherapy compared to when used alone.
- On Thursday, October 27 and Friday, October 28, at the Grand Hyatt San Francisco Airport, located at 55 South McDonnell Road in San Francisco, Estrigenix Therapeutics Inc. announced a new study on hormone replacement therapy.
저자 크레딧: Radhika Pawar
- Report ID: 4982
- Published Date: May 31, 2023
- Report Format: PDF, PPT
